Key result
Hypotensive therapy with ACE inhibitors and angiotensin receptor blockers provides nephroprotective effects in patients with chronic kidney disease and glomerulonephritis.
Answers are grounded in this paper and cite their sources.
This review highlights the nephroprotective effects of ACE inhibitors and ARBs and the importance of safe blood pressure reduction in patients with CKD and glomerulonephritis.
The literature review presents current international data on the principles of choice of hypotensive therapy tactics in patients with chronic kidney disease and glomerulonephritis. safe levels of blood pressure reduction, reflected in the regulatory documents of European and American nephrological and cardiological associations, methods of their control are discussed. Data on the nephroprotective effects of the main classes of hypotensive drugs – angiotensin-converting enzyme inhibitors and angiotensin receptor blockers – are presented. The necessity of monitoring the safety of hypotensive therapy in glomerulonephritis with chronic kidney disease using methods of blood pressure monitoring is emphasized.
No takes yet. Share an insight, caveat, or question.
Теплова et al. (2021) conducted a review in Arterial hypertension in patients with chronic kidney disease and glomerulonephritis. Hypotensive therapy (ACE inhibitors and ARBs) was evaluated. Hypotensive therapy with ACE inhibitors and angiotensin receptor blockers provides nephroprotective effects in patients with chronic kidney disease and glomerulonephritis.
Synapse has enriched 10 related papers. Consider them for comparative context: